Skip to content
Peptigraph home

Peptides for Fatigue

The peptides people most often research for fatigue, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Peptides listed
1
With human trials
1
FDA approved (any use)
0
Showing 1 peptide · ordered by search interest for this goal
  1. MOTS-cMitochondrial-derived peptideHuman RCT evidence, 4 of 4Scientific reports 2021, PMID 34413391Human3Animal2Summarised3PCAC voted 7–5 for 503A (Jul 2026)For fatigueOverview
Read this first

What this list does not show

Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.

Search interest is not evidence

This list follows what people search for and discuss. It says nothing about how well any peptide works.

Animal results may not carry over

Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.

Approval covers specific uses

An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.

Combinations are a separate question

Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.

Fatigue is a symptom, not a disease

MedlinePlus states that fatigue itself is not a disease but a symptom with many possible causes.[2]

It also says fatigue can signal a mental or physical condition when it persists.[2]

What the listed peptides have on fatigue

MOTS-c, the only peptide on the hub list, has 3 human-only and 2 animal papers on fatigue and no randomised trial.

Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); mots-c human only 3, animal only 2, rct 0. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.

In mice, MOTS-c significantly enhanced physical performance in young, middle-aged and old animals.[3]

In Barth syndrome, SS-31 was followed at 36 weeks in part 2 by significant improvements in 6-minute walk distance (+95.9 m) and in the symptom score (-2.1 points).[4]

In a comparison with another drug, selank had similar anxiolytic effects and also antiasthenic and psychostimulant effects.[5]

A single case report describes VIP replacement within a multi-part programme after which symptoms resolved, which cannot isolate the peptide.[6]

Common questions

What are the best peptides for fatigue?

In the evidence files SS-31 has fatigue-related scores in Barth syndrome, but neither primary endpoint was met in part 1.[4]

Are there peptides for chronic fatigue?

The one case report found mixes VIP replacement with several other interventions.[6]

Sources

  1. 1Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
  2. 2Official web pageOfficial web page · web page
  3. 3MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
  4. 4A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.Genetics in medicine : official journal of the American College of Medical Genetics · 2021PMID 33077895Accessed 2 Oct 2026
  5. 5[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2008PMID 18454096Accessed 2 Oct 2026
  6. 6Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures.The American journal of case reports · 2016PMID 27165859Accessed 2 Oct 2026

Found an error? Report a correction.